The meningococcal vaccine protects against infections caused by Neisseria meningitidis, a bacterium that can invade the bloodstream and the lining of the brain and spinal cord. These infections are rare but devastating: 5 to 10% of patients die within 48 hours, and 10 to 20% of survivors develop permanent complications including hearing loss, brain damage, or limb amputations. There are several versions of the vaccine, each targeting different strains of the bacterium, and most adolescents in the U.S. are recommended to receive at least one type.
Types of Meningococcal Vaccines
The bacterium that causes meningococcal disease comes in several serogroups, essentially different strains identified by their outer coating. The vaccines are organized around which serogroups they cover:
- MenACWY vaccines protect against four serogroups: A, C, W, and Y. This is the one most teens receive as a routine shot.
- MenB vaccines target serogroup B specifically, which is responsible for a significant share of cases in adolescents and young adults.
- MenABCWY vaccines are newer pentavalent vaccines that combine protection against all five serogroups (A, B, C, W, and Y) in a single product. The first of these, Penbraya, was approved by the FDA in October 2023. This option simplifies things for people who would otherwise need separate MenACWY and MenB shots at the same visit.
How the Vaccine Works
Most modern meningococcal vaccines are conjugate vaccines, meaning they attach a piece of the bacterium’s sugar coating to a carrier protein. This design matters because the immune system handles sugar molecules and proteins very differently. When your immune cells encounter a sugar molecule on its own, they can recognize it but can’t mount a lasting defense. The process stalls before your body creates the long-lived memory cells that would protect you in the future.
By linking the sugar to a protein, conjugate vaccines trick the immune system into treating the sugar like a protein threat. This activates a deeper immune response that produces high-quality antibodies and, critically, memory cells that stick around for years. It’s the reason conjugate vaccines replaced older polysaccharide-only vaccines, which offered weaker, shorter-lived protection.
MenB vaccines work a bit differently. Because serogroup B’s sugar coating closely resembles molecules found on human nerve cells, targeting it directly could cause the immune system to attack the body’s own tissue. Instead, MenB vaccines use surface proteins from the bacterium to trigger immunity.
Who Should Get Vaccinated
The CDC recommends all 11- to 12-year-olds receive a MenACWY vaccine, with a booster at age 16. That booster is important because protection fades over time, and the years between 16 and 21 carry the highest risk for meningococcal disease in adolescents, partly due to close-quarters living in college dorms and increased social contact.
MenB vaccination follows a different approach. Rather than a blanket recommendation, the CDC suggests a shared decision-making conversation between teens (or their parents) and a healthcare provider to decide whether the vaccine makes sense for that individual. For those who opt in, two doses spaced six months apart are standard. The preferred age is 16 through 18 to maximize protection during the highest-risk years. Students heading to college in less than six months can receive an accelerated three-dose series to build protection faster.
Higher-Risk Groups
Certain people face a substantially greater risk of meningococcal disease and are strongly recommended to get both MenACWY and MenB vaccines. This includes people who have a damaged or missing spleen, those with complement deficiencies (a part of the immune system that helps fight bacterial infections), people living with HIV, and anyone exposed during an active outbreak. For these individuals, the MenB schedule is more intensive: a three-dose primary series, a booster one year after completing the series, and additional boosters every two to three years thereafter.
Travel Requirements
Meningococcal vaccination is recommended or required in certain travel situations. The “meningitis belt” of Sub-Saharan Africa, a band of countries stretching from Senegal to Ethiopia, sees regular epidemics during the dry season from December through June. The CDC recommends MenACWY vaccination for travelers aged two months and older visiting this region during those months, especially anyone who will have prolonged contact with local populations.
Saudi Arabia requires proof of meningococcal vaccination for anyone aged one year or older making the Hajj or Umrah pilgrimages. Conjugate vaccine documentation is accepted for up to five years before arrival, though it must have been given at least 10 days prior. Many U.S. colleges also require proof of MenACWY vaccination for incoming students living in dormitories.
Side Effects
The most common reaction across all meningococcal vaccines is soreness at the injection site. Beyond that, the side effect profile varies somewhat by vaccine type.
MenACWY vaccines tend to be milder. Injection site pain occurs in roughly 20 to 45% of recipients depending on the specific product, with headache (27 to 30%), muscle aches (27 to 35%), and general fatigue (19 to 26%) rounding out the most frequent complaints.
MenB vaccines produce noticeably more short-term side effects. Pain at the injection site affects 83% or more of recipients. Fatigue hits at least 35%, headache at least 33%, and muscle pain at least 30%. These reactions are typically strongest after the first dose and resolve within a day or two.
The pentavalent MenABCWY vaccines, which combine both types, have the most robust side effect profile, consistent with what you’d expect from getting both vaccines at once. Injection site pain was reported in 84 to 89% of recipients in clinical trials, fatigue in about half, and headache in 40 to 47%. Joint pain and chills each occurred in roughly one in five people. These numbers sound high, but the reactions are overwhelmingly mild and temporary.
How Long Protection Lasts
MenACWY protection fades meaningfully over several years, which is exactly why the booster at 16 exists. A preteen vaccinated at 11 or 12 would have declining antibody levels by the time they enter the highest-risk window in their late teens. The age-16 booster restores and extends that protection through the college years.
MenB vaccine durability is less well established. The limited effectiveness data available comes primarily from a mass vaccination campaign in Canada among people under 20, where vaccine effectiveness was estimated at 79% in the four years following vaccination. For people at ongoing increased risk, the CDC recommends MenB boosters every two to three years to maintain protection.
Why the Disease Is So Dangerous
Meningococcal disease can take two forms: meningitis (infection of the membranes surrounding the brain and spinal cord) and septicemia (infection in the bloodstream). Both can progress from mild, flu-like symptoms to life-threatening illness within hours. Even with modern hospital treatment, 5 to 10% of patients die within the first 24 to 48 hours.
Survivors of severe disease often face lasting consequences. Amputations occur in 4 to 8% of children with severe septic shock and about 3% of adolescents and adults. Other long-term effects include hearing loss, cognitive difficulties, severe scarring requiring skin grafts, and neurological damage. The speed and severity of the disease is the central reason vaccination is recommended before exposure, since there is very little time to react once symptoms appear.